STOCK TITAN

[SCHEDULE 13D/A] GeneDx Holdings Corp. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A
Rhea-AI Filing Summary

Amendment No. 9 to the Schedule 13D for GeneDx Holdings Corp. updates ownership and voting information for a group led by Eli Casdin and Keith Meister. The filing shows that Eli Casdin beneficially owns 3,599,671 shares (12.4%) and Keith A. Meister beneficially owns 3,630,826 shares (12.5%) of the Class A common stock, based on 28,726,248 shares outstanding as of July 24, 2025.

The filing attributes 3,007,164 shares (10.5%) to Casdin Partners Master Fund, L.P. and 3,058,629 shares (10.6%) to investment funds advised by Corvex Management LP. Certain reported holdings include shares issuable upon exercise of warrants and vested options (including 204,141 private placement warrants exercisable at $379.50 per share). The funds for the purchases listed were from the working capital of Casdin Partners Master Fund, L.P. Transactions in the past 60 days are reported in Exhibit B. The Amendment supplements earlier Schedule 13D filings and includes a joint filing agreement and transaction schedule as exhibits.

Emendamento n. 9 al Schedule 13D di GeneDx Holdings Corp. aggiorna le informazioni su partecipazioni e diritti di voto per un gruppo guidato da Eli Casdin e Keith Meister. La comunicazione indica che Eli Casdin detiene soggettivamente 3.599.671 azioni (12,4%) e Keith A. Meister detiene soggettivamente 3.630.826 azioni (12,5%) di azioni ordinarie di Classe A, su un totale di 28.726.248 azioni in circolazione al 24 luglio 2025.

Il documento attribuisce 3.007.164 azioni (10,5%) al Casdin Partners Master Fund, L.P. e 3.058.629 azioni (10,6%) a fondi d'investimento consigliati da Corvex Management LP. Alcune partecipazioni riportate comprendono azioni derivanti dall'esercizio di warrant e opzioni maturate (inclusi 204.141 warrant di collocamento privato esercitabili a $379,50 per azione). I fondi per gli acquisti indicati provengono dal capitale circolante del Casdin Partners Master Fund, L.P. Le operazioni degli ultimi 60 giorni sono riportate nell'Allegato B. L'emendamento integra precedenti Schedule 13D e include come allegati un accordo di deposito congiunto e il calendario delle transazioni.

Enmienda n.º 9 al Schedule 13D de GeneDx Holdings Corp. actualiza la información de propiedad y voto de un grupo liderado por Eli Casdin y Keith Meister. La presentación muestra que Eli Casdin posee beneficiariamente 3.599.671 acciones (12,4%) y Keith A. Meister posee beneficiariamente 3.630.826 acciones (12,5%) de las acciones ordinarias Clase A, sobre un total de 28.726.248 acciones en circulación a fecha del 24 de julio de 2025.

El documento atribuye 3.007.164 acciones (10,5%) a Casdin Partners Master Fund, L.P. y 3.058.629 acciones (10,6%) a fondos asesorados por Corvex Management LP. Algunas posiciones reportadas incluyen acciones susceptibles de emitirse por el ejercicio de warrants y opciones devengadas (incluyendo 204.141 warrants de colocación privada ejercitables a $379,50 por acción). Los fondos para las compras indicadas provinieron del capital de trabajo de Casdin Partners Master Fund, L.P. Las transacciones de los últimos 60 días se informan en el Anexo B. La enmienda complementa presentaciones previas en Schedule 13D e incluye como anexos un acuerdo de presentación conjunta y el programa de transacciones.

수정서 제9호는 GeneDx Holdings Corp.의 Schedule 13D를 갱신하여 Eli Casdin과 Keith Meister가 주도하는 그룹의 소유 및 의결권 정보를 업데이트합니다. 제출서에 따르면 Eli Casdin은 3,599,671주(12.4%)를 실질적으로 보유하고 있으며 Keith A. Meister는 3,630,826주(12.5%)를 실질적으로 보유하고 있고, 총 발행주식수는 2025년 7월 24일 기준 28,726,248주입니다.

제출서에는 Casdin Partners Master Fund, L.P.에 3,007,164주(10.5%), Corvex Management LP가 자문하는 투자펀드에 3,058,629주(10.6%)가 귀속된 것으로 기재되어 있습니다. 보고된 일부 보유는 워런트 및 이미 부여된 옵션의 행사로 발행 가능한 주식을 포함하며(그중 204,141개 사모 워런트는 주당 $379.50에 행사 가능), 기재된 매수 자금은 Casdin Partners Master Fund, L.P.의 운전 자본에서 충당되었습니다. 지난 60일간의 거래는 부록 B에 보고되어 있습니다. 이 수정서는 이전의 Schedule 13D 제출을 보완하며, 공동 제출 합의서 및 거래 일정이 부속서로 포함되어 있습니다.

Avenant n°9 au Schedule 13D de GeneDx Holdings Corp. mettant à jour les informations de participation et de vote d’un groupe dirigé par Eli Casdin et Keith Meister. Le dépôt indique qu’Eli Casdin détient bénéficiairement 3 599 671 actions (12,4%) et Keith A. Meister détient bénéficiairement 3 630 826 actions (12,5%) des actions ordinaires de classe A, sur un total de 28 726 248 actions en circulation au 24 juillet 2025.

Le document attribue 3 007 164 actions (10,5%) au Casdin Partners Master Fund, L.P. et 3 058 629 actions (10,6%) à des fonds conseillés par Corvex Management LP. Certaines positions déclarées incluent des actions susceptibles d’être émises à l’exercice de warrants et d’options acquises (dont 204 141 warrants de placement privé exerçables à 379,50 $ par action). Les fonds destinés aux achats indiqués provenaient du fonds de roulement du Casdin Partners Master Fund, L.P. Les transactions des 60 derniers jours sont rapportées en Annexe B. L’avenant complète les précédents dépôts Schedule 13D et comprend en annexes un accord de dépôt conjoint et le calendrier des transactions.

Nachtrag Nr. 9 zum Schedule 13D von GeneDx Holdings Corp. aktualisiert die Angaben zu Beteiligungen und Stimmrechten einer von Eli Casdin und Keith Meister geführten Gruppe. Die Einreichung weist aus, dass Eli Casdin wirtschaftlich 3.599.671 Aktien (12,4%) und Keith A. Meister wirtschaftlich 3.630.826 Aktien (12,5%) der Stammaktien Klasse A besitzt, bei insgesamt 28.726.248 ausstehenden Aktien zum 24. Juli 2025.

Der Bericht schreibt dem Casdin Partners Master Fund, L.P. 3.007.164 Aktien (10,5%) und den von Corvex Management LP beratenen Investmentfonds 3.058.629 Aktien (10,6%) zu. Bestimmte ausgewiesene Bestände umfassen Aktien, die durch Ausübung von Warrants und bereits ausgeübten Optionen entstehen können (darunter 204.141 Private Placement-Warrants, ausübbar zu $379,50 je Aktie). Die Mittel für die aufgeführten Käufe stammten aus dem Umlaufvermögen des Casdin Partners Master Fund, L.P. Transaktionen der letzten 60 Tage sind in Anlage B aufgeführt. Der Nachtrag ergänzt frühere Schedule 13D-Einreichungen und enthält als Anlagen eine gemeinsame Einreichungsvereinbarung und einen Transaktionsplan.

Positive
  • Material disclosure of ownership: Two principal reporting persons disclose >10% holdings each, providing clear transparency to the market.
  • Funding clarity: Purchases for the Casdin-held shares were made from the working capital of Casdin Partners Master Fund, L.P., with no borrowed funds used for purchases (other than ordinary working capital borrowings).
  • Exhibits filed: Joint Filing Agreement and a Schedule of Transactions (Exhibits A and B) are included to document coordination and recent transactions.
Negative
  • Potential dilution: The reported holdings include 204,141 private placement warrants exercisable at $379.50 per share and various vested options and RSU-related shares that can increase the share count.
  • Concentrated ownership: Significant shared beneficial ownership and shared voting power are concentrated among related parties, which could centralize control in a small group of affiliated holders.

Insights

TL;DR: Two activist-aligned investors report double-digit stakes, representing a material ownership position that may affect corporate governance.

The filing documents that Eli Casdin and Keith Meister, through affiliated vehicles, each hold roughly 12% of Class A stock, with institutional vehicles owning just over 10% each. These stakes are material relative to the 28.7 million shares outstanding and could influence board or strategic outcomes. The inclusion of exercisable private placement warrants and vested options increases the potential share count that these parties can control. Funding was from working capital of the Casdin fund, not borrowed funds for purchases. Overall, this is a clear, material ownership disclosure that investors should treat as a governance development.

TL;DR: Reported shared voting and dispositive power across related entities creates a concentrated, coordinated ownership bloc exceeding 10%.

The Schedule 13D/A shows shared voting and dispositive power among related entities (CMLS Holdings LLC, C-LSH LLC, M-LSH LLC, Casdin entities, and Corvex-related funds), resulting in concentrated influence. The filing identifies specific securities that expand voting potential, including private placement warrants and vested options. Exhibits confirm recent open-market transactions. The structure and level of ownership are sufficiently material to be considered impactful for governance and strategic discussions at the issuer.

Emendamento n. 9 al Schedule 13D di GeneDx Holdings Corp. aggiorna le informazioni su partecipazioni e diritti di voto per un gruppo guidato da Eli Casdin e Keith Meister. La comunicazione indica che Eli Casdin detiene soggettivamente 3.599.671 azioni (12,4%) e Keith A. Meister detiene soggettivamente 3.630.826 azioni (12,5%) di azioni ordinarie di Classe A, su un totale di 28.726.248 azioni in circolazione al 24 luglio 2025.

Il documento attribuisce 3.007.164 azioni (10,5%) al Casdin Partners Master Fund, L.P. e 3.058.629 azioni (10,6%) a fondi d'investimento consigliati da Corvex Management LP. Alcune partecipazioni riportate comprendono azioni derivanti dall'esercizio di warrant e opzioni maturate (inclusi 204.141 warrant di collocamento privato esercitabili a $379,50 per azione). I fondi per gli acquisti indicati provengono dal capitale circolante del Casdin Partners Master Fund, L.P. Le operazioni degli ultimi 60 giorni sono riportate nell'Allegato B. L'emendamento integra precedenti Schedule 13D e include come allegati un accordo di deposito congiunto e il calendario delle transazioni.

Enmienda n.º 9 al Schedule 13D de GeneDx Holdings Corp. actualiza la información de propiedad y voto de un grupo liderado por Eli Casdin y Keith Meister. La presentación muestra que Eli Casdin posee beneficiariamente 3.599.671 acciones (12,4%) y Keith A. Meister posee beneficiariamente 3.630.826 acciones (12,5%) de las acciones ordinarias Clase A, sobre un total de 28.726.248 acciones en circulación a fecha del 24 de julio de 2025.

El documento atribuye 3.007.164 acciones (10,5%) a Casdin Partners Master Fund, L.P. y 3.058.629 acciones (10,6%) a fondos asesorados por Corvex Management LP. Algunas posiciones reportadas incluyen acciones susceptibles de emitirse por el ejercicio de warrants y opciones devengadas (incluyendo 204.141 warrants de colocación privada ejercitables a $379,50 por acción). Los fondos para las compras indicadas provinieron del capital de trabajo de Casdin Partners Master Fund, L.P. Las transacciones de los últimos 60 días se informan en el Anexo B. La enmienda complementa presentaciones previas en Schedule 13D e incluye como anexos un acuerdo de presentación conjunta y el programa de transacciones.

수정서 제9호는 GeneDx Holdings Corp.의 Schedule 13D를 갱신하여 Eli Casdin과 Keith Meister가 주도하는 그룹의 소유 및 의결권 정보를 업데이트합니다. 제출서에 따르면 Eli Casdin은 3,599,671주(12.4%)를 실질적으로 보유하고 있으며 Keith A. Meister는 3,630,826주(12.5%)를 실질적으로 보유하고 있고, 총 발행주식수는 2025년 7월 24일 기준 28,726,248주입니다.

제출서에는 Casdin Partners Master Fund, L.P.에 3,007,164주(10.5%), Corvex Management LP가 자문하는 투자펀드에 3,058,629주(10.6%)가 귀속된 것으로 기재되어 있습니다. 보고된 일부 보유는 워런트 및 이미 부여된 옵션의 행사로 발행 가능한 주식을 포함하며(그중 204,141개 사모 워런트는 주당 $379.50에 행사 가능), 기재된 매수 자금은 Casdin Partners Master Fund, L.P.의 운전 자본에서 충당되었습니다. 지난 60일간의 거래는 부록 B에 보고되어 있습니다. 이 수정서는 이전의 Schedule 13D 제출을 보완하며, 공동 제출 합의서 및 거래 일정이 부속서로 포함되어 있습니다.

Avenant n°9 au Schedule 13D de GeneDx Holdings Corp. mettant à jour les informations de participation et de vote d’un groupe dirigé par Eli Casdin et Keith Meister. Le dépôt indique qu’Eli Casdin détient bénéficiairement 3 599 671 actions (12,4%) et Keith A. Meister détient bénéficiairement 3 630 826 actions (12,5%) des actions ordinaires de classe A, sur un total de 28 726 248 actions en circulation au 24 juillet 2025.

Le document attribue 3 007 164 actions (10,5%) au Casdin Partners Master Fund, L.P. et 3 058 629 actions (10,6%) à des fonds conseillés par Corvex Management LP. Certaines positions déclarées incluent des actions susceptibles d’être émises à l’exercice de warrants et d’options acquises (dont 204 141 warrants de placement privé exerçables à 379,50 $ par action). Les fonds destinés aux achats indiqués provenaient du fonds de roulement du Casdin Partners Master Fund, L.P. Les transactions des 60 derniers jours sont rapportées en Annexe B. L’avenant complète les précédents dépôts Schedule 13D et comprend en annexes un accord de dépôt conjoint et le calendrier des transactions.

Nachtrag Nr. 9 zum Schedule 13D von GeneDx Holdings Corp. aktualisiert die Angaben zu Beteiligungen und Stimmrechten einer von Eli Casdin und Keith Meister geführten Gruppe. Die Einreichung weist aus, dass Eli Casdin wirtschaftlich 3.599.671 Aktien (12,4%) und Keith A. Meister wirtschaftlich 3.630.826 Aktien (12,5%) der Stammaktien Klasse A besitzt, bei insgesamt 28.726.248 ausstehenden Aktien zum 24. Juli 2025.

Der Bericht schreibt dem Casdin Partners Master Fund, L.P. 3.007.164 Aktien (10,5%) und den von Corvex Management LP beratenen Investmentfonds 3.058.629 Aktien (10,6%) zu. Bestimmte ausgewiesene Bestände umfassen Aktien, die durch Ausübung von Warrants und bereits ausgeübten Optionen entstehen können (darunter 204.141 Private Placement-Warrants, ausübbar zu $379,50 je Aktie). Die Mittel für die aufgeführten Käufe stammten aus dem Umlaufvermögen des Casdin Partners Master Fund, L.P. Transaktionen der letzten 60 Tage sind in Anlage B aufgeführt. Der Nachtrag ergänzt frühere Schedule 13D-Einreichungen und enthält als Anlagen eine gemeinsame Einreichungsvereinbarung und einen Transaktionsplan.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


CMLS Holdings LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Manager
Date:08/26/2025
C-LSH LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member
Date:08/26/2025
M-LSH LLC
Signature:By: /s/ Keith A. Meister
Name/Title:Keith A. Meister, Managing Member
Date:08/26/2025
Casdin Capital, LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member
Date:08/26/2025
Casdin Partners Master Fund, L.P.
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member of its General Partner
Date:08/26/2025
Casdin Partners GP, LLC
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin, Managing Member
Date:08/26/2025
Eli Casdin
Signature:By: /s/ Eli Casdin
Name/Title:Eli Casdin
Date:08/26/2025
Keith A. Meister
Signature:By: /s/ Keith A. Meister
Name/Title:Keith A. Meister
Date:08/26/2025
Corvex Management LP
Signature:By: /s/ Keith A. Meister
Name/Title:Keith Meister, Managing Partner
Date:08/26/2025
Comments accompanying signature:
* This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

FAQ

How many shares of GeneDx (WGS) does Eli Casdin beneficially own according to the Schedule 13D/A?

Eli Casdin is reported to beneficially own 3,599,671 shares, representing 12.4% of the Class A shares outstanding based on 28,726,248 shares.

What percentage of GeneDx (WGS) does Keith A. Meister beneficially own?

Keith A. Meister is reported to beneficially own 3,630,826 shares, representing 12.5% of the Class A shares outstanding.

Do the reported holdings include any warrants or options for GeneDx (WGS)?

Yes. The reported holdings include 204,141 private placement warrants exercisable at $379.50 per share and various fully vested options and restricted stock units disclosed in the filing.

What source of funds was used to purchase the shares reported in the filing?

The funds for the purchase of the shares listed in Exhibit B came from the working capital of Casdin Partners Master Fund, L.P. No borrowed funds were used to purchase the Shares other than ordinary working capital borrowings.

Are there recent transactions by the reporting persons in the last 60 days?

Yes. The filing states that transactions in the securities of the issuer during the past sixty days are set forth in Exhibit B, and that all such transactions were carried out in open market transactions.
GeneDx Holdings Corp

NASDAQ:WGS

WGS Rankings

WGS Latest News

WGS Latest SEC Filings

WGS Stock Data

3.50B
25.18M
12.46%
110.88%
12.67%
Diagnostics & Research
Services-health Services
Link
United States
STAMFORD